Alembic Pharma gets USFDA tentative nod for generic of Rexulti

Alembic Pharma gets USFDA tentative nod for generic of Rexulti

It is indicated as adjunctive therapy alongside antidepressants for the treatment of major depressive disorders and schizophrenia

FPJ Web DeskUpdated: Thursday, March 09, 2023, 10:25 AM IST
article-image
Alembic Pharma gets USFDA tentative nod for generic of Rexulti | Image: Wikipedia (Representative)

Alembic Pharmaceuticals Ltd has received tentative approval from the US Food and Drug Administration for brexpiprazole tablets in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths, according to an exchange filing.

The drug is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets.

It is indicated as adjunctive therapy alongside antidepressants for the treatment of major depressive disorders and schizophrenia.

According to information from IQVIA, the drug's sales for the fiscal year that ended in December 2022 totaled about $1.6 billion.

The shares of the company traded 0.7% higher at ₹515.75 on NSE, at 09:15 IST.

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Government to make ₹4,000 crore from over-subscribed share sale for Coal India

Government to make ₹4,000 crore from over-subscribed share sale for Coal India

RBI proposes rules for payment system operators to strengthen cybersecurity

RBI proposes rules for payment system operators to strengthen cybersecurity

Go First may relaunch operations in two weeks as part of revival plan submitted to DGCA

Go First may relaunch operations in two weeks as part of revival plan submitted to DGCA

From Nano to ₹13,000 crore EV battery plant, a look at Tata's top projects Gujarat

From Nano to ₹13,000 crore EV battery plant, a look at Tata's top projects Gujarat

Income Tax refunds were issued within 16 days on average in FY23

Income Tax refunds were issued within 16 days on average in FY23